Drug Trial Radar · NCT07866066
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,300
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Sep 6, 2028
Study completion Dec 5, 2028
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Maridebart cafraglutideDrug
Administered subcutaneously.
SemaglutideDrug
Administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]Time frame: Baseline to Week 68
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Acclaim Clinical Research
San Diego, California · Recruiting
Bioclinical Research Alliance
Miami, Florida · Recruiting
Indago Research and Health Center
Miami Lakes, Florida · Recruiting
Clinical Research Center Of Florida
Pompano Beach, Florida · Recruiting
Conquest Research - Winter Park
Winter Park, Florida · Recruiting
Virginia Nephrology Group
Arlington, Virginia · Recruiting
Eastside Research Associates Health Research
Redmond, Washington · Recruiting
Dr T G Elliott Incorporated - BC Diabetes
Vancouver, British Columbia, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.